Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

Pneumonia is a lung infection that annually impacts millions of people around the globe, according to the Centers for Disease ...

According to the investigators of a newly published study on the waning of pneumococcal vaccines responses in people with inflammatory arthritis, pneumonia is a major cause of mortality in this ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs) targeting both paediatric and adult populations. This partnership extension ...

Sanofi (SNYNF, SNY) and SK bioscience have entered an expanded agreement to develop, license and commercialize next-generation ...

Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and ...